|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: LIPG |
Gene summary for LIPG |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | LIPG | Gene ID | 9388 |
| Gene name | lipase G, endothelial type | |
| Gene Alias | EDL | |
| Cytomap | 18q21.1 | |
| Gene Type | protein-coding | GO ID | GO:0006082 | UniProtAcc | B4DTR8 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 9388 | LIPG | HTA11_1391_2000001011 | Human | Colorectum | AD | 6.69e-06 | 6.66e-01 | -0.059 |
| 9388 | LIPG | HTA11_7663_2000001011 | Human | Colorectum | SER | 1.48e-04 | 7.39e-01 | 0.0131 |
| 9388 | LIPG | HTA11_7696_3000711011 | Human | Colorectum | AD | 1.63e-09 | 4.45e-01 | 0.0674 |
| 9388 | LIPG | HTA11_6818_2000001011 | Human | Colorectum | AD | 1.03e-02 | 4.72e-01 | 0.0112 |
| 9388 | LIPG | HTA11_6818_2000001021 | Human | Colorectum | AD | 4.64e-02 | 3.55e-01 | 0.0588 |
| 9388 | LIPG | HTA11_99999965062_69753 | Human | Colorectum | MSI-H | 6.11e-04 | 8.75e-01 | 0.3487 |
| 9388 | LIPG | HTA11_99999965104_69814 | Human | Colorectum | MSS | 5.29e-06 | 5.28e-01 | 0.281 |
| 9388 | LIPG | Adj_PTCwithHT_6 | Human | Thyroid | HT | 1.57e-08 | -5.85e-01 | 0.02 |
| 9388 | LIPG | Adj_PTCwithHT_8 | Human | Thyroid | HT | 4.82e-03 | -4.96e-01 | 0.0267 |
| 9388 | LIPG | PTCwithHT_6 | Human | Thyroid | HT | 5.45e-11 | -5.91e-01 | 0.02 |
| 9388 | LIPG | PTCwithHT_8 | Human | Thyroid | HT | 6.59e-08 | -5.61e-01 | 0.0351 |
| 9388 | LIPG | PTCwithoutHT_2 | Human | Thyroid | PTC | 1.16e-04 | -4.97e-01 | 0.0419 |
| 9388 | LIPG | male-WTA | Human | Thyroid | PTC | 6.71e-46 | 2.27e-01 | 0.1037 |
| 9388 | LIPG | PTC01 | Human | Thyroid | PTC | 1.63e-12 | -1.08e-01 | 0.1899 |
| 9388 | LIPG | PTC05 | Human | Thyroid | PTC | 3.30e-04 | -6.77e-02 | 0.2065 |
| 9388 | LIPG | PTC06 | Human | Thyroid | PTC | 1.47e-06 | 1.18e-01 | 0.2057 |
| 9388 | LIPG | PTC07 | Human | Thyroid | PTC | 2.36e-12 | 1.61e-01 | 0.2044 |
| 9388 | LIPG | ATC08 | Human | Thyroid | ATC | 3.87e-02 | -5.98e-01 | 0.0541 |
| 9388 | LIPG | ATC09 | Human | Thyroid | ATC | 4.12e-03 | -3.96e-01 | 0.2871 |
| 9388 | LIPG | ATC12 | Human | Thyroid | ATC | 2.20e-12 | -5.76e-01 | 0.34 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0031667 | Colorectum | AD | response to nutrient levels | 138/3918 | 474/18723 | 1.22e-05 | 2.68e-04 | 138 |
| GO:0016042 | Colorectum | AD | lipid catabolic process | 97/3918 | 320/18723 | 4.31e-05 | 7.56e-04 | 97 |
| GO:0006631 | Colorectum | AD | fatty acid metabolic process | 114/3918 | 390/18723 | 5.58e-05 | 9.44e-04 | 114 |
| GO:0044242 | Colorectum | AD | cellular lipid catabolic process | 66/3918 | 214/18723 | 3.96e-04 | 4.50e-03 | 66 |
| GO:0010876 | Colorectum | AD | lipid localization | 120/3918 | 448/18723 | 1.59e-03 | 1.33e-02 | 120 |
| GO:0006869 | Colorectum | AD | lipid transport | 108/3918 | 398/18723 | 1.67e-03 | 1.39e-02 | 108 |
| GO:0006644 | Colorectum | AD | phospholipid metabolic process | 101/3918 | 383/18723 | 5.80e-03 | 3.67e-02 | 101 |
| GO:00160421 | Colorectum | SER | lipid catabolic process | 77/2897 | 320/18723 | 3.52e-05 | 9.18e-04 | 77 |
| GO:00316671 | Colorectum | SER | response to nutrient levels | 106/2897 | 474/18723 | 3.94e-05 | 1.00e-03 | 106 |
| GO:00442421 | Colorectum | SER | cellular lipid catabolic process | 51/2897 | 214/18723 | 8.60e-04 | 1.05e-02 | 51 |
| GO:0046486 | Colorectum | SER | glycerolipid metabolic process | 82/2897 | 392/18723 | 2.26e-03 | 2.17e-02 | 82 |
| GO:00066441 | Colorectum | SER | phospholipid metabolic process | 79/2897 | 383/18723 | 3.94e-03 | 3.24e-02 | 79 |
| GO:00066311 | Colorectum | SER | fatty acid metabolic process | 79/2897 | 390/18723 | 6.34e-03 | 4.56e-02 | 79 |
| GO:00316672 | Colorectum | MSS | response to nutrient levels | 125/3467 | 474/18723 | 1.24e-05 | 2.88e-04 | 125 |
| GO:00066312 | Colorectum | MSS | fatty acid metabolic process | 95/3467 | 390/18723 | 2.20e-03 | 1.84e-02 | 95 |
| GO:0046394 | Colorectum | MSS | carboxylic acid biosynthetic process | 76/3467 | 314/18723 | 6.71e-03 | 4.38e-02 | 76 |
| GO:00108761 | Colorectum | MSS | lipid localization | 104/3467 | 448/18723 | 6.76e-03 | 4.38e-02 | 104 |
| GO:00160422 | Colorectum | MSS | lipid catabolic process | 77/3467 | 320/18723 | 7.43e-03 | 4.71e-02 | 77 |
| GO:0016053 | Colorectum | MSS | organic acid biosynthetic process | 76/3467 | 316/18723 | 7.88e-03 | 4.84e-02 | 76 |
| GO:00463941 | Colorectum | MSI-H | carboxylic acid biosynthetic process | 36/1319 | 314/18723 | 2.68e-03 | 3.48e-02 | 36 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa005612 | Colorectum | MSS | Glycerolipid metabolism | 23/1875 | 63/8465 | 6.55e-03 | 2.64e-02 | 1.62e-02 | 23 |
| hsa005613 | Colorectum | MSS | Glycerolipid metabolism | 23/1875 | 63/8465 | 6.55e-03 | 2.64e-02 | 1.62e-02 | 23 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| LIPG | SNV | Missense_Mutation | novel | c.1276N>A | p.Leu426Met | p.L426M | Q9Y5X9 | protein_coding | tolerated(0.1) | possibly_damaging(0.577) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| LIPG | SNV | Missense_Mutation | novel | c.1160T>G | p.Val387Gly | p.V387G | Q9Y5X9 | protein_coding | tolerated(0.09) | possibly_damaging(0.601) | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| LIPG | SNV | Missense_Mutation | c.364G>C | p.Asp122His | p.D122H | Q9Y5X9 | protein_coding | deleterious(0) | probably_damaging(0.963) | TCGA-AR-A0TS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| LIPG | insertion | Nonsense_Mutation | novel | c.900_901insTGCTGCACAGCTGGTCTGCATCACCCTACTTAGCACTTATT | p.Asn301CysfsTer11 | p.N301Cfs*11 | Q9Y5X9 | protein_coding | TCGA-A8-A07O-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | CR | |||
| LIPG | insertion | Frame_Shift_Ins | novel | c.1197_1198insATAAGTGGGGTGGAGGGGGTGCCCAGGAATCATTTTGATAA | p.Val400IlefsTer25 | p.V400Ifs*25 | Q9Y5X9 | protein_coding | TCGA-A8-A0A6-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | epirubicin | CR | ||
| LIPG | SNV | Missense_Mutation | c.944N>A | p.Arg315His | p.R315H | Q9Y5X9 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| LIPG | SNV | Missense_Mutation | rs756501637 | c.1451N>A | p.Arg484Gln | p.R484Q | Q9Y5X9 | protein_coding | tolerated(0.17) | benign(0.011) | TCGA-C5-A7X3-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | SD |
| LIPG | SNV | Missense_Mutation | rs750648857 | c.766N>A | p.Asp256Asn | p.D256N | Q9Y5X9 | protein_coding | tolerated(0.28) | benign(0.21) | TCGA-EK-A3GM-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
| LIPG | SNV | Missense_Mutation | c.313C>G | p.Leu105Val | p.L105V | Q9Y5X9 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-IR-A3LH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| LIPG | SNV | Missense_Mutation | rs750648857 | c.766N>A | p.Asp256Asn | p.D256N | Q9Y5X9 | protein_coding | tolerated(0.28) | benign(0.21) | TCGA-VS-A953-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 9388 | LIPG | DRUGGABLE GENOME, ENZYME, LIPASE, CELL SURFACE, PHOSPHOLIPASE | GSK-264220A | |||
| 9388 | LIPG | DRUGGABLE GENOME, ENZYME, LIPASE, CELL SURFACE, PHOSPHOLIPASE | inhibitor | 404859111 | ||
| 9388 | LIPG | DRUGGABLE GENOME, ENZYME, LIPASE, CELL SURFACE, PHOSPHOLIPASE | inhibitor | 178103308 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |